AUSTIN, Texas, Sept. 19, 2017 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (SCV) and Oncolix, Inc. (Pink Sheets: AEPP), a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian cancer, today announced that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/9-12-17-smallcapvoice-interview-with-oncolix-inc-aepp.
Michael T. Redman called in to SmallCapVoice.com to go over the business model, management, the ongoing Phase I human clinical trial in ovarian cancer patients and the FDA granting Prolanta Orphan Drug status for the treatment of ovarian cancer in this new interview. Recently the Company consummated a private placement of debt securities, resulting in gross proceeds of $2.0 million. Newbridge Securities Corporation, through LifeTech Capital, acted as lead placement agent for the offering and as financial advisor for the merger.
In the interview Mr. Redman stated, “Our management team is quite diverse because we have experience running companies both big …